Henry Pertinez

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 17 papers. Top paper: “Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial”.

Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial

The Journal of Infectious Diseases(2025)10.1093/infdis/jiaf195

N/A

0.104DataRank · unranked

1 citations

Gareth Platt, Charles A. Peloquin, M B Brooks, Julia Coit, Gustavo E. Velásquez +12 more

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

British Journal of Clinical Pharmacology(2020)10.1111/bcp.14619

N/A

0DataRank · unranked

58 citations

Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley +18 more

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

Journal of Antimicrobial Chemotherapy(2021)10.1093/jac/dkab135

N/A

0DataRank · unranked

29 citations

Rajith K. R. Rajoli, Saye Khoo, Andrew Owen, Henry Pertinez

Development of a highly sensitive bioanalytical assay for the quantification of favipiravir

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.02.03.429628

N/A

0DataRank · unranked

13 citations

Megan Neary, Usman Arshad, Lee Tatham, Henry Pertinez, Helen Box +6 more

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

medRxiv(2021)10.1101/2021.09.10.21263376

N/A

0DataRank · unranked

0 citations

Richard J. Fitzgerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin +27 more

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.23.477397

N/A

0DataRank · unranked

12 citations

Anja Kipar, Joanne Sharp, Edyta Kijak, Joanne Herriott, Megan Neary +12 more

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans

Pharmaceutics(2023)10.3390/pharmaceutics15122709

N/A

0DataRank · unranked

7 citations

Rajith K. R. Rajoli, Henry Pertinez, Lalitkumar K. Vora, Fabiana Volpe‐Zanutto, Ryan F. Donnelly +5 more

Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations

Pharmaceutics(2023)10.3390/pharmaceutics15071835

N/A

0DataRank · unranked

6 citations

J. Hobson, Neill J. Liptrott, Edward Makarov, Amer Al‐khouja, Lee Tatham +12 more

Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

Clinical Pharmacology & Therapeutics(2020)10.1002/cpt.1909

N/A

0DataRank · unranked

168 citations

Henry Pertinez, Helen Box, Lee Tatham, Rajith K. R. Rajoli, Paul Curley +17 more

Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters

Journal of Antimicrobial Chemotherapy(2023)10.1093/jac/dkad362

N/A

0DataRank · unranked

4 citations

Joanne Sharp, Shaun H. Pennington, Edyta Kijak, Lee Tatham, Claire H Caygill +20 more

Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters

Viruses(2023)10.3390/v15112161

N/A

0DataRank · unranked

3 citations

Megan Neary, Joanne Sharp, Joanne Herriott, Edyta Kijak, Chloe Bramwell +11 more

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00481-23

N/A

0DataRank · unranked

2 citations

Si‐Yang Li, Henry Pertinez, Fabrice Betoudji, Jin Lee, Steve P. Rannard +4 more

Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.12.536604

N/A

0DataRank · unranked

0 citations

Si‐Yang Li, Henry Pertinez, Fabrice Betoudji, Jin Lee, Steve P. Rannard +4 more

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case

Microbiology Spectrum(2024)10.1128/spectrum.03916-23

N/A

0DataRank · unranked

5 citations

Anja Kipar, Joanne Sharp, Edyta Kijak, Joanne Herriott, Megan Neary +12 more

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters

Viruses(2024)10.3390/v16121838

N/A

0DataRank · unranked

2 citations

Eduardo Gallardo‐Toledo, Joanne Sharp, Joanne Herriott, Edyta Kijak, Chloe Bramwell +16 more

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.03.583160

N/A

0DataRank · unranked

2 citations

Amit Kaushik, Paul Curley, Usman Arshad, Eman El‐Khateeb, Si‐Yang Li +11 more

Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research

Journal of Chromatography B(2023)10.1016/j.jchromb.2023.123823

N/A

0DataRank · unranked

6 citations

Usman Arshad, Lee Tatham, Henry Pertinez, Helen Box, Rajith K. R. Rajoli +7 more